在慢性胃炎的Helicobacter pylori根除过程中尿路代谢概况
Wen-Ting An1, Yu-Xia Hao2, Hong-Xia Li3
1Department of Pharmacy, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
World journal of clinical cases
|February 28, 2024
概括
这项研究揭示了慢性胃炎患者在Helicobacter pylori根除之前和之后的尿路代谢特征. 确定了参与特定途径的关键代谢物和蛋白质,为治疗机制提供了洞察力.
科学领域:
- 胃肠病学 胃肠病学
- 代谢学 代谢学 代谢学
- 系统生物学 系统生物学
背景情况:
- *Helicobacter pylori* (H. pylori) 感染是慢性胃炎的普遍原因,影响了全球近一半的人口.
- 根除H. pylori是一种常见的治疗方法,但其潜在机制需要进一步阐明.
- 泌尿代谢学为了解胃病治疗机制提供了一种非侵入性方法,但临床研究尚不够.
研究的目的:
- 在经过H. pylori根除的慢性胃炎患者中调查尿路代谢概况.
- 为了确定主要的尿路代谢物和受H. pylori根除疗法影响的代谢途径.
主要方法:
- 使用基于液体染色学和质谱学 (LC-MS) 的代谢学.
- 网络药理学被整合到分析代谢物-蛋白相互作用中.
- 使用了临床后续研究设计.
主要成果:
- 在H. pylori根除之前和之后观察到不同的尿路代谢概况.
- 主要受调节的代谢物包括cys-aconitic acid,酸,L-tyrosine,L-phenylalanine,L-tryptophan和hippuric acid. 这些代谢物中含有
- 已识别的代谢途径:氨酸代谢,氨酸-氨酸-氨酸生物合成,酸盐循环,以及氧酸盐/二碳酸盐代谢.
- 确定了关键的蛋白质:MPO,COMT,TPO,TH,EPX,CMA1,DDC,TPH1和LPO. 这些蛋白质是最重要的.
结论:
- 这项研究为尿路代谢产物在评估H. pylori根除治疗中的作用提供了新的视角.
- 这些发现有助于了解H. pylori阳性慢性胃炎的评估和预后.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
397
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
397
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
117
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
117
01:23Gastritis III: Clinical Manifestations and Management
246
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
246
01:26Peptic Ulcer Disease IV: Management
92
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
92
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
484
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
484
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
430
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
430